High tumor amplification burden is associated with TP53 mutations in the pan-cancer setting. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: Joshi, Rushikesh S.; Boichard, Amelie; Adashek, Jacob J.; Kurzrock, Razelle
• Is Part Of: Cancer biology & therapy. Volume 23:Issue 1(2022)
• Page Start: 1
• Page End: 6
• Publication Date: 2022-12-31
• Subjects: cancer genes -- next-generation sequencing -- amplifications -- TP53; 616.99406
• DOI: 10.1080/15384047.2022.2128608
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: Next-generation sequencing data is fundamentally changing the clinical management of patients with cancer. The most frequent genomic alterations in malignancy are mutations and amplifications, with a subset of tumors having multiple amplifications – "amplificators". We sought to understand the molecular correlates of high tumor amplification burden in a pan-cancer context. Using both national registries and a single-institution dataset, our results demonstrate that cancers with TP53 mutations (as compared to those with wild-type TP53 ) exhibited significantly higher tumor amplification burden across all datasets. Amplifications, generally associated with overexpression, may be potentially actionable secondary consequences of TP53 mutations.